Comparison of Vaginal Hyaluronic Acid Treatment Over Autologous Platelet Rich Plasma Treatment for Genitourinary Syndrome of Menopause

Launched by KANUNI SULTAN SULEYMAN TRAINING AND RESEARCH HOSPITAL · Oct 5, 2022

Keywords

ClinConnect Summary

This clinical trial is comparing two treatments for women experiencing genitourinary syndrome of menopause (GSM), which can cause uncomfortable symptoms like dryness and irritation in the vaginal area. The study is looking at how effective vaginal hyaluronic acid is compared to a treatment called platelet-rich plasma, which involves using a sample of your own blood to create a healing serum. Women who are menopausal and experiencing GSM symptoms may be eligible to participate in this trial, but certain conditions, like active infections or recent pelvic surgeries, might exclude some candidates.

Participants in the trial will receive either treatment and will go through assessments to measure how well the treatments work and if there are any side effects. This includes completing questionnaires, undergoing pelvic examinations, and testing the vaginal environment. It's important to know that the trial is currently recruiting participants, and it's a great opportunity for women looking for relief from their symptoms in a supportive research setting.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Women with menopause
• • Patients with symptoms of genitourinary syndrome of menopause
• Exclusion Criteria:
• • Genitourinary bleeding or infection without a definitive diagnosis
• • Coagulopathy
• • Allergy to medication or therapy related to the treatment
• • Chronic disease that might influence the outcome
• • Using medication that might influence the outcome in 30 days
• • Using hormone or steroid within 8 weeks
• • Personal history of vulvovaginal conditions such as lichen sclerosis, lichen planus, vulvovaginal condyloma, vaginal intraepithelial neoplasia, vaginal carcinoma, history of cervical or other gynecologic cancer, radical pelvic surgery, acute or recurrent urinary tract infection, genital infection, history of vaginal or pelvic radiation
• • Chronic pelvic pain, current pelvic tension myalgia/muscle hypertonicity
• • Pelvic organ prolapse greater than stage II
• • Pelvic surgery within 6 months
• • Known allergy to lidocaine or prilocaine
• • Use of vaginal moisturizers, lubricants, or homeopathic preparations within 2 weeks of therapy
• • Immunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy.